// App-Quantinova.ai

TPS7569 : Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Researchers

Presenter

  • Catherine Thieblemont

Principal Investigators

  • Michael Roost Clausen

  • Anna Sureda Balari

  • Pier Luigi Zinzani

  • Christopher Fox

  • Su Young Kim

  • Signe Diness Vindeloev

  • Pieternella Lugtenburg

Medical Centers

  • Assistance Publique & Hôpitaux de Paris (APHP), Hopital Saint-Louis, Hemato-Oncologie, Université de Paris, Paris, France

  • Vejle Hospital, Vejle, Denmark

  • Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet del Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • Lymphoma and Chronic Lymphoproliferative Syndromes Unit, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • AbbVie, Inc., North Chicago, IL

  • Genmab, Copenhagen, Denmark

  • On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology,Rotterdam,Netherlands

Locations

  • France

  • Denmark

  • Spain

  • Italy

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Diffuse large B-cell lymphoma

  • Follicular lymphoma

  • B cell lymphomas

  • B-Cell Non-Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • B-cell lymphoma 6

  • cMYC

Drug/Treatment

  • Bendamustine

  • Gemcitabine

  • Oxaliplatin

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT04663347

  • NCT04628494

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved